(redirected from Immunotoxins)
Also found in: Medical, Encyclopedia.


 (ĭm′yə-nō-tŏk′sĭn, ĭ-myo͞o′-)
A hybrid molecule formed by binding a toxin to a monoclonal antibody, used to destroy tumor cells.


a toxin with immunosuppressive effects


(ˌɪm yə noʊˈtɒk sɪn, ɪˌmyu-)

a monoclonal antibody linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact.
Mentioned in ?
References in periodicals archive ?
While immunotoxins kill particular classes of nerve cells, some of those cells may not be devoted to regulating and sensing pain.
The candidates are both immunotoxins comprising an antibody fragment that targets the CD22 receptor on B-lymphocytes fused to a toxin molecule.
The immunotoxins have lived up to their billing as cancer killers, but they also trigger changes in cells lining blood vessels.
Because a variety of disorders are treated with bone marrow transplants, the use of immunotoxins to eliminate harmful cells prior to the procedure could have a significant impact in increasing transplant success rates and reducing hospital time.
Aflatoxins are immunotoxins that frequently contaminate staple foods in The Gambia and other parts of sub-Saharan Africa, resulting in high exposure throughout life.
The company has four technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy (ADEPT).
Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells.
This makes it much easier for antibody-based drugs, known as immunotoxins, to attack the cancerous cells.
They then introduced special antibodies with toxins and found that the immunotoxins penetrated the leukaemia cells and killed them faster.
Oncomatrix carries out the development of Diagnostic devices and Antibody-Drug Conjugates and Immunotoxins against these novel targets, in collaboration with reference research centers, universities and hospitals in Europe and USA, such as National Jewish Health, Case Western Reserve University, University of Stuttgart, Hospital Universitario Marques de Valdecilla and Hospital Central de Asturias.
for immunotoxins - including agents in clinical development -- Biosimilar insulins likely from 2015 - transformation of that market -- Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.
Keynote Presentation: "Novel Approach to B and T Epitope Removal from Immunotoxins with Retention of High Cytotoxic Activity," featuring Ira Pastan, M.